RISK-FACTORS FOR COMPLICATIONS OF CHRONIC ANTICOAGULATION - A MULTICENTER STUDY

被引:606
作者
FIHN, SD
MCDONELL, M
MARTIN, D
HENIKOFF, J
VERMES, D
KENT, D
WHITE, RH
机构
[1] SEATTLE VET AFFAIRS MED CTR, HLTH SERV RES & DEV FIELD PROGRAM 152, 1660 S COLUMBIAN WAY, SEATTLE, WA 98108 USA
[2] UNIV CALIF DAVIS, SACRAMENTO MED CTR, DEPT GEN MED, SACRAMENTO, CA 95817 USA
关键词
WARFARIN; THROMBOEMBOLISM; HEMORRHAGE; PROTHROMBIN TIME;
D O I
10.7326/0003-4819-118-7-199304010-00005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To define risk factors for complications that occur during warfarin therapy. Design: Retrospective cohort study. Setting: Five anticoagulation clinics. Patients: Nine hundred twenty-eight consecutive patients receiving 1103 courses of warfarin. Main Outcome Measures: Hemorrhagic and thromboembolic complications. Results: In 1950 patient-years of follow-up, there were 1332 bleeding events (4 were classified as fatal, 31 as life-threatening, 226 as serious, and 1071 as minor). The cumulative incidence of fatal bleeding was 1% at 1 year and 2% at 3 years. The cumulative incidences of first episodes of life-threatening and serious bleeding at 1, 2, 4, and 8 years were 1%, 2%, 5%, and 9% and 12%, 20%, 28%, and 40%, respectively. Of 156 patients who had a serious or life-threatening hemorrhage, 32% suffered a recurrence, typically within 1 year. Independent predictors of a first episode of serious bleeding included a mean prothrombin time ratio (PTR) of 2.0 or more during the course of treatment (relative risk, 3.0; 95% Cl, 1.9 to 4.7); recent initiation of warfarin therapy (relative risk during the first 3 months compared with the rest of the first year, the second year, and anytime thereafter, 1.9 [Cl, 1.3 to 3.0], 3.0 [Cl, 1.8 to 4.8], and 5.9 [Cl, 3.8 to 9.3], respectively); variability of the PTR over time (relative risk for the highest compared with the lowest tertile, 1.6 [Cl, 1.2 to 2.7]); and the presence of 3 or more comorbid conditions (RR, 1.4 [Cl, 1.1 to 2.5]). Age, reason for anticoagulation, use of interfering drugs, and hypertension were not associated with risk for bleeding. The risk for a thromboembolic complication at a PTR of less than 1.3 was 3.6 (Cl, 2.1 to 6.4) times higher than at a PTR of 1.3 to 1.5. Conclusions: The incidence of warfarin-associated bleeding may be reduced by attending to modifiable risk factors (that is, highly variable PTRs and values greater than 2.0), frequent monitoring early in treatment, and careful patient selection. Older age, in and of itself, is not a risk factor.
引用
收藏
页码:511 / 520
页数:10
相关论文
共 40 条
[31]   THE ST JUDE VALVE PROSTHESIS - ANALYSIS OF THE CLINICAL-RESULTS IN 815 IMPLANTS AND THE NEED FOR SYSTEMIC ANTICOAGULATION [J].
MYERS, ML ;
LAWRIE, GM ;
CRAWFORD, ES ;
HOWELL, JF ;
MORRIS, GC ;
GLAESER, DH ;
DEBAKEY, ME .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1989, 13 (01) :57-62
[32]   10-YEAR RESULTS WITH THE ST-JUDE MEDICAL PROSTHESIS [J].
NAIR, CK ;
MOHIUDDIN, SM ;
HILLEMAN, DE ;
SCHULTZ, R ;
BAILEY, RT ;
COOK, CT ;
SKETCH, MH .
AMERICAN JOURNAL OF CARDIOLOGY, 1990, 65 (03) :217-225
[33]  
PETERSEN P, 1989, LANCET, V1, P175
[34]   DURATION OF WARFARIN ANTICOAGULANT-THERAPY AND THE PROBABILITIES OF RECURRENT THROMBOEMBOLISM AND HEMORRHAGE [J].
PETITTI, DB ;
STROM, BL ;
MELMON, KL .
AMERICAN JOURNAL OF MEDICINE, 1986, 81 (02) :255-259
[35]   ASYMPTOTICALLY EFFICIENT RANK INVARIANT TEST PROCEDURES [J].
PETO, R ;
PETO, J .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES A-GENERAL, 1972, 135 :185-&
[36]   COMPLICATIONS OF LONG-TERM ANTICOAGULATION [J].
PETTY, GW ;
LENNIHAN, L ;
MOHR, JP ;
HAUSER, WA ;
WEITZ, J ;
OWEN, J ;
TOWEY, C .
ANNALS OF NEUROLOGY, 1988, 23 (06) :570-574
[37]   TRIAL OF DIFFERENT INTENSITIES OF ANTICOAGULATION IN PATIENTS WITH PROSTHETIC HEART-VALVES [J].
SAOUR, JN ;
SIECK, JO ;
MAMO, LAR ;
GALLUS, AS .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (07) :428-432
[38]   THE EFFECT OF WARFARIN ON MORTALITY AND REINFARCTION AFTER MYOCARDIAL-INFARCTION [J].
SMITH, P ;
ARNESEN, H ;
HOLME, I .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (03) :147-152
[39]  
1979, DHEW PHS791352 NAT C
[40]  
1990, NEW ENGL J MED, V322, P863